Carrier MA, Tu SS - Texas Intellectual Property Law Journal
The authors refute the argument that pharmaceutical companies’ accumulation of patent thickets is analogous to technology companies’ patenting practices. Firms’ litigation of method of use patents and increasing use of continuation patents to block generic entry highlight how pharmaceutical patent thickets, unlike thickets in other industries, are designed to be anti-competitive.
VIEW SOURCE
Costa E, Kesselheim AS - Journal of Law, Medicine, & Ethics
Kirby-Rivera L, Feldman WB, Kim M, Kosmopoulou G, Kesselheim AS, Tu SS - Journal of Law, Medicine, & Ethics
Eisenkraft Klein D, Kesselheim AS - Health Policy